HOOKIPA Pharma Inc. (HOOK)
Largest Insider Buys in Sector
HOOK Stock Price History Chart
HOOK Stock Performance
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive …
Insider Activity of HOOKIPA Pharma Inc.
Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $0 and sold $0 worth of HOOKIPA Pharma Inc. stock.
On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $3.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.
List of Insider Buy and Sell Transactions, HOOKIPA Pharma Inc.
| 2023-08-21 | Chief Financial Officer | 7,000 0.0091% | $0.72 | $5,075 | -7.79% | |||
| 2023-08-16 | Chief Financial Officer | 8,000 0.0103% | $0.71 | $5,712 | -5.67% | |||
| 2023-07-11 | Chief Executive Officer | 5,000 0.007% | $0.83 | $4,142 | -14.57% | |||
| 2023-07-07 | Chief Executive Officer | 5,000 0.0068% | $0.81 | $4,050 | -14.50% | |||
| 2023-07-05 | Chief Executive Officer | 5,000 0.0071% | $0.89 | $4,450 | -18.79% | |||
| 2023-07-03 | Chief Executive Officer | 5,000 0.0072% | $0.89 | $4,456 | -16.94% | |||
| 2023-06-30 | Chief Financial Officer | 12,000 0.0166% | $0.88 | $10,560 | -19.15% | |||
| 2021-12-21 | Sale | Chief Medical Officer | 14,949 0.0457% | $2.49 | $37,223 | -37.90% | ||
| 2021-04-21 | Sale | 10 percent owner | 328,620 0.9448% | $11.60 | $3.81M | -58.05% | ||
| 2021-03-29 | Sale | 10 percent owner | 36,829 0.1234% | $13.67 | $503,570 | -54.96% | ||
| 2021-03-26 | Sale | 10 percent owner | 35,171 0.1167% | $13.69 | $481,642 | -54.91% | ||
| 2021-03-25 | Sale | 10 percent owner | 28,546 0.093% | $13.12 | $374,569 | -53.55% | ||
| 2021-03-24 | Sale | 10 percent owner | 52,690 0.1841% | $13.70 | $721,616 | -52.05% | ||
| 2021-03-23 | Sale | 10 percent owner | 40,000 0.1374% | $13.91 | $556,476 | -53.53% | ||
| 2021-03-22 | Sale | 10 percent owner | 40,534 0.1369% | $14.54 | $589,263 | -55.71% | ||
| 2021-03-19 | Sale | 10 percent owner | 166,230 0.5544% | $14.60 | $2.43M | -56.39% | ||
| 2020-12-17 | Sale | Chief Medical Officer | 27,979 0.1031% | $11.74 | $328,343 | -20.23% | ||
| 2020-12-16 | Sale | Chief Medical Officer | 380 0.0014% | $11.70 | $4,446 | -18.84% | ||
| 2020-10-02 | Sale | 10 percent owner | 300 0.0011% | $10.00 | $3,000 | +13.55% | ||
| 2020-09-15 | Sale | 10 percent owner | 41,597 0.1949% | $12.61 | $524,477 | +5.48% |
Insider Historical Profitability
| SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3177574 32.9111% | $2.35 | 1 | 12 | <0.0001% |
| Forbion Capital Fund II Cooperatief U.A. | 10 percent owner | 2494173 25.8329% | $2.35 | 1 | 0 | <0.0001% |
| BAKER BROS. ADVISORS LP | 820729 8.5005% | $2.35 | 1 | 0 | <0.0001% | |
| Aldag Jorn | Chief Executive Officer | 71952 0.7452% | $2.35 | 4 | 0 | <0.0001% |
| Kandera Reinhard | Chief Financial Officer | 43092 0.4463% | $2.35 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $5.79B | 82.14 | 8.13M | 0% | +$0 | 41.56 | |
| Artal Group S A | $4.03B | 57.27 | 5.67M | 0% | +$0 | 17.63 | |
| Tupelo Capital Management LLC | $3.93B | 55.76 | 5.52M | 0% | +$0 | 96.35 | |
| Ecor1 Capital Llc | $3.27B | 46.44 | 4.6M | 0% | +$0 | 22.96 | |
| Fidelity Investments | $2.39B | 33.94 | 3.36M | 0% | +$0 | 0.16 |